BOA2019 - SBRT/SABR for Oligometastases
With increasing frequency, local therapy in the form of SBRT or hypofractionated radiation is being applied to patients with oligometastatic cancers as a means of attempting to improve survival outcomes, durability of systemic therapy treatment responses, etc. However, it is apparent that not all of these indications are driven by evidence-based approaches or data from larger scale clinical trials. With this session, we aim to provide an updated view of the principles relevant to treatment of oligometastatic disease and the data supporting its utilization.
The meeting is designed to meet the interests of radiation oncologists and residents.
- Identify current evidence that exists for the use of local therapy for oligometastatic cancers
- Apply best practice for. optimal dose of radiation, timing of treatment (front line vs consolidation vs oligoprogression), integration with systemic therapy such as immunotherapy (for abscopal benefit), etc.
- Analyze active trials or ones under development that will provide a stronger basis for changes in standards of care for local therapy use in oligometastatic disease states.
The following persons served as faculty for this activity:
Laura Dawson, MD, FASTRO is employed at Princess Margaret Hospital and has a research grant from Merch and a patent/license with Raysearch.
Puneeth Iyengar, MD, PhD is employed at UT Southwestern Medical Center and has nothing to disclose.
Additionally, the Education and CME/MOC Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.00 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.00 self-assessment credits.
- 1.25 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
- No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
- No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
- ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.